Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Ripretinib, sold under the brand name Qinlock, is a medication for the treatment of adults with advanced gastrointestinal stromal tumor (GIST), a type of tumor that originates in the gastrointestinal tract. It is taken by mouth. Ripretinib inhibits the activity of the kinases KIT and PDGFRA, which helps keep cancer cells from growing.
Read the full article on WikipediaMetastatic or unresectable malignant gastrointestinal stromal tumour Clinical criteria: Treatment Phase: Initial treatment The condition must not be resectable, AND The treatment must be as monotherapy, AND The condition must have progressed despite treatment with all drugs PBS-listed specifically for this PBS-indication; OR The condition must have progressed despite each of: (i) treatment with a drug PBS-listed specifically listed for this PBS-indication, (ii) an intolerance/expected intolerance to all other drugs PBS-listed for this specific PBS-indication, AND Patient must have a WHO performance status of 2 or less. Treatment criteria: Patient must be undergoing PBS-subsidised treatment with this drug for the first time - retreatment/continuing treatment beyond the available repeat prescription is not permitted under this listing; see 'Continuing treatment' Treatment Phase listing to continue PBS-subsidised treatment in a patient without disease progression.
Working under the parallel aged-care framework? Aged-care equivalent →